CDK

Cyclin dependent kinase

CDK

CDK Isoform Specific Products:

CDK Isoform Comparison

CDK Related Products (821)
Recombinant Proteins (39)
Antibodies (43)
CDK Isoform Comparison

By Effects:	Controls (2) Ligands (2) Inhibitors (734) Substrate (1) Degraders (39) Antagonist (1) Activators (6) Modulators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-147007

β-catenin-IN-3	Inhibitor
β-catenin-IN-3 (Compound C2) is a selective β-catenin inhibitor. β-catenin-IN-3 binds to allosteric site on the surface of β-catenin with K_D calculated at 54.96 nM. β-catenin-IN-3 selectively inhibits β-catenin via targeting a cryptic allosteric modulation site, lowers its cellular load. β-catenin-IN-3 significantly reduces viability of β-catenin driven cancer cells, and triggers β-catenin degradation via proteasome system in β-catenin-overexpressing cancer cells.

HY-50767S

Palbociclib-d₈	Inhibitor	99.84%
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-111518

JH-XI-10-02	Inhibitor	99.82%
JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC₅₀ of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19.

HY-103019B

(-)-Enitociclib	Inhibitor	99.85%
(-)-Enitociclib ((R)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.

HY-117203A

CDK12-IN-E9	Inhibitor	99.97%
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC₅₀> 1 μM.

HY-114338A

Dalpiciclib hydrochloride	Inhibitor	98.22%
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma.

HY-145694

CDK5-IN-3	Inhibitor	99.49%
CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC₅₀s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD).

HY-150082

CP681301	Inhibitor	99.18%
CP681301 is a potent CDK5 inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila.

HY-13231

CDK9-IN-1	Inhibitor	98.52%
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

HY-152219

CLK1-IN-2	Inhibitor	98.73%
CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC₅₀ value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza.

HY-16462

CDK9-IN-2	Inhibitor	99.37%
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

HY-101257B

YKL-5-124 TFA	Inhibitor	99.74%
YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status.

HY-111379

EHT 5372	Inhibitor	98.12%
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively.

HY-15569

NU6102	Inhibitor	99.23%
NU6102 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM).

HY-114712

SJ572403	Activator	98.92%
SJ572403 (SJ403) is a p27^Kip1 inhibitor. SJ572403 has high specificity for specific regions within the D2 subdomain of p27-KID with a K_d value of 2.2 mM. SJ572403 can be used for the research of diseases associated with intrinsically disordered proteins (IDPs).

HY-134911

HS-243	Inhibitor	99.95%
HS-243 is a potent and selective IRAK-4 and IRAK-1 inhibitor, with IC₅₀ values of 20 and 24 nM. HS-243 shows minimal TAK1 (transforming growth factor β-activated kinase 1) inhibition activity, with a IC₅₀ of 0.5 μM. HS-243 shows anti-inflammatory and anticancer activity.

HY-P2559

CDK7/9 tide		99.92%
CDK7/9 tide is peptide substrate for CDK7 or CDK9.

HY-148062

RSS0680		98.03%
RSS0680 (Example 22) is a bifunctional compound targeted protein degradation of kinases. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used for research of disease or disorder mediated by aberrant kinase activity.(Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078))

HY-104013

Aminopurvalanol A	Inhibitor	98.25%
Aminopurvalanol A is a potent, selective, and cell permeable inhibitor of Cyclins/Cdk complexes. Aminopurvalanol A preferentially targets the G2/M-phase transition inhibiting cancer cell differentiation. Aminopurvalanol A causes the inhibition of sperm fertilizing ability via the inhibition of physiological capacitation-dependent actin polymerization.

HY-117049

Leucettine L41	Inhibitor	98.70%
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC₅₀s = 0.04, 0.035, 0.015, and 4.5 µM, respectively). Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ_25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ_25-35 in the same model.

CDK Isoform Comparison

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Pho85

CDK Degraders, Inhibitors, Antagonists & Activators

Product Name	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDK11	CDK12	CDK13	CDK14	CDK16	CDK19	CDC	CLK	Pho85	Purity

Palbociclib

Cdk4/cyclin D3, IC₅₀: 9 nM
Cdk4/cyclin D1, IC₅₀: 11 nM

Cdk6/cyclin D2, IC₅₀: 16 nM

99.94%

Abemaciclib

CDK1/cyclinB1, IC₅₀: 1627 nM

CDK2/cyclinE, IC₅₀: 504 nM

Cdk4/cyclin D1, IC₅₀: 2 nM

CDK5/p35, IC₅₀: 287 nM
Cdk5/p25, IC₅₀: 355 nM

CDK6/cyclinD1, IC₅₀: 10 nM

CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM

CDK9/cyclinT1, IC₅₀: 57 nM

99.97%

Ribociclib

CDK4, IC₅₀: 10 nM

CDK6, IC₅₀: 39 nM

99.94%

Ro-3306

CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM

CDK2/cyclinE, Ki: 340 nM

99.83%

Dinaciclib

CDK1, IC₅₀: 3 nM

CDK2, IC₅₀: 1 nM

CDK5, IC₅₀: 1 nM

CDK9, IC₅₀: 4 nM

99.64%

YJ1206

CDK12

CDK13

Flavopiridol

CDK1/Cyc B1, IC₅₀: 30 nM

CDK2/Cyc E, IC₅₀: 170 nM

CDK4/Cyc D1, IC₅₀: 100 nM

99.73%

GSK3326595

CDK4

CDK6

99.83%

(R)-Roscovitine

cdc2/cyclin B, IC₅₀: 0.65 μM

cdk2/cyclin A, IC₅₀: 0.7 μM
Cdk2/cyclin E2, IC₅₀: 0.7 μM

CDK5/p35, IC₅₀: 0.16 μM

99.53%

Palbociclib monohydrochloride

Cdk4/cyclin D3, IC₅₀: 9 nM
Cdk4/cyclin D1, IC₅₀: 11 nM

Cdk6/cyclin D2, IC₅₀: 16 nM

99.98%

THZ1

CDK7, IC₅₀: 3.2 nM

99.84%

Abemaciclib methanesulfonate

CDK1/cyclinB1, IC₅₀: 1627 nM

CDK2/cyclinE, IC₅₀: 504 nM

Cdk4/cyclin D1, IC₅₀: 2 nM

Cdk5/p25, IC₅₀: 355 nM
CDK5/p35, IC₅₀: 287 nM

CDK6/cyclinD1, IC₅₀: 10 nM

CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM

CDK9/cyclinT1, IC₅₀: 57 nM

99.95%

AZD4573

CDK9, IC₅₀: 4 nM

99.98%

Palbociclib isethionate

Cdk4/cyclin D3, IC₅₀: 9 nM
Cdk4/cyclin D1, IC₅₀: 11 nM

Cdk6/cyclin D2, IC₅₀: 16 nM

99.99%

THZ531

CDK7, IC₅₀: 8.5 μM

CDK9, IC₅₀: 10.5 μM

CDK12, IC₅₀: 158 nM

CDK13, IC₅₀: 69 nM

99.86%

Kenpaullone

Cdk1/cyclin B, IC₅₀: 0.4 μM

cdk2/cyclin A, IC₅₀: 0.68 μM
CDK2/cyclinE, IC₅₀: 7.5 μM

Cdk5/p25, IC₅₀: 0.85 μM

98.20%

Wogonin

CDK8

99.92%

Toyocamycin

CDK2/cyclinA, IC₅₀: 0.67 μM

Cdk4/cyclin D3, IC₅₀: 15 μM

cdk6/cyclin D3, IC₅₀: >10 μM

CDK7/Mat1/cyclinH1, IC₅₀: 2.8 μM

CDK9/cyclinT1, IC₅₀: 79 nM

99.78%

SR-4835

CDK12, IC₅₀: 99 nM
CDK12, Kd: 98 nM

CDK13, Kd: 4.9 nM

99.73%

Palbociclib hydrochloride

Cdk4/cyclin D3, IC₅₀: 9 nM
Cdk4/cyclin D1, IC₅₀: 11 nM

Cdk6/cyclin D2, IC₅₀: 16 nM

99.89%

SY-5609

CDK2, Ki: 2600 nM

CDK7, Kd: 0.065 nM

CDK9, Ki: 960 nM

CDK12, Ki: 870 nM

99.33%

SNS-032

CDK1, IC₅₀: 480 nM

CDK2, IC₅₀: 38 nM

CDK4, IC₅₀: 925 nM

CDK7, IC₅₀: 62 nM

CDK9, IC₅₀: 4 nM

99.54%

GSK 3 Inhibitor IX

Cdk1/cyclin B, IC₅₀: 320 nM

cdk2/cyclin A, IC₅₀: 300 nM

Cdk4/cyclin D1, IC₅₀: 10 μM

CDK5/p35, IC₅₀: 80 nM

99.73%

Amantadine

CDK2

99.90%

NVP-2

CDK9, IC₅₀: 0.5 nM

99.60%

OTS964 hydrochloride

CDK11B, Kd: 40 nM

99.74%

Tagtociclib hydrate

CDK2/cyclin E1, Ki: 1.16 nM

99.95%

Samuraciclib hydrochloride

CDK1, IC₅₀: 1.8 μM

CDK2, IC₅₀: 578 nM

CDK4, IC₅₀: 49 μM

CDK5, IC₅₀: 9.4 μM

CDK6, IC₅₀: 34 μM

CDK7, IC₅₀: 41 nM

CDK9, IC₅₀: 1.2 μM

99.98%

Simurosertib

Cdc7, IC₅₀: <0.3 nM

99.94%

JNJ-7706621

Cdk1/cyclin B, IC₅₀: 9 nM

CDK2/cyclinE, IC₅₀: 3 nM
cdk2/cyclin A, IC₅₀: 4 nM

CDK3/Cyclin E, IC₅₀: 58 nM

Cdk4/cyclin D1, IC₅₀: 253 nM

CDK6/cyclinD1, IC₅₀: 175 nM

99.91%

hSMG-1 inhibitor 11j

CDK1, IC₅₀: 32 μM

CDK2, IC₅₀: 7.1 μM

99.82%

AT7519

Cdk1/cyclin B, IC₅₀: 210 nM

cdk2/cyclin A, IC₅₀: 47 nM

Cdk4/cyclin D1, IC₅₀: 100 nM

CDK5/p35, IC₅₀: 13 nM

cdk6/cyclin D3, IC₅₀: 170 nM

CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM

CDK9/Cyclin T, IC₅₀: 10 nM

99.76%

KB-0742 dihydrochloride

CDK9/cyclinT1, IC₅₀: 6 nM

99.24%

MBQ-167

Cdc42, IC₅₀: 78 nM

99.64%

(+)-Enitociclib

CDK9/CycT1, IC₅₀: 3 nM

99.89%

CPS2

CDK2, IC₅₀: 24 nM

99.33%

BI-1347

CDK8, IC₅₀: 1.1 nM

99.84%

AZD-5438

cdk1-cyclin B1, IC₅₀: 16 nM

cdk2-cyclin E, IC₅₀: 6 nM
cdk2-cyclin A, IC₅₀: 45 nM

cdk4-cyclin D1, IC₅₀: 449 nM

cdk5-p25, IC₅₀: 14 nM

cdk6-cyclin D3, IC₅₀: 21 nM

cdk7-cyclin H, IC₅₀: 821 nM

cdk9-cyclin T, IC₅₀: 20 nM

99.91%

TG003

CLK1, IC₅₀: 20 nM
CLK2, IC₅₀: 200 nM
CLK4, IC₅₀: 15 nM

99.57%

Ribociclib hydrochloride

CDK4, IC₅₀: 10 nM

CDK6, IC₅₀: 39 nM

99.95%

Fadraciclib

CDK2

CDK9

99.78%

Flavopiridol Hydrochloride

CDK1/Cyc B1, IC₅₀: 30 nM

CDK2/Cyc E, IC₅₀: 170 nM

CDK4/Cyc D1, IC₅₀: 100 nM

99.73%

AS2863619

CDK8, IC₅₀: 0.61 nM

CDK19, IC₅₀: 4.28 nM

99.94%

BSJ-4-116

CDK12, IC₅₀: 6 nM

98.73%

Ribociclib succinate

CDK4, IC₅₀: 10 nM

CDK6, IC₅₀: 39 nM

99.93%

CVT-313

Cdk1/cyclin B, IC₅₀: 4.2 μM

cdk2/cyclin A, IC₅₀: 0.5 μM

Cdk4/cyclin D1, IC₅₀: 215 μM

99.90%

(R)-CR8

Cdk1/cyclin B, IC₅₀: 0.09 μM

cdk2/cyclin A, IC₅₀: 0.072 μM
CDK2/cyclinE, IC₅₀: 0.041 μM

Cdk5/p25, IC₅₀: 0.11 μM

CDK7/cyclin H, IC₅₀: 1.1 μM

CDK9/Cyclin T, IC₅₀: 0.18 μM

99.61%

YKL-5-124

CDK2, IC₅₀: 1300 nM

CDK7, IC₅₀: 53.5 nM
CDK7/Mat1/CycH, IC₅₀: 9.7 nM

CDK9, IC₅₀: 3020 nM

98.79%

SLK/STK10-IN-1

CLK2, IC₅₀: 39 nM

99.78%

CLK-IN-T3

CLK1, IC₅₀: 0.67 nM
CLK2, IC₅₀: 15 nM
CLK3, IC₅₀: 110 nM

98.63%

BTX-A51

CDK7, Kd: 1.3 nM

CDK9, Kd: 4 nM

98.58%

NG 52

cdc2-cyclin B, IC₅₀: 0.34 μM

Pho85p, IC₅₀: 2 nM

99.88%

MSC2530818

CDK8, IC₅₀: 2.6 nM

99.62%

hSMG-1 inhibitor 11e

CDK1, IC₅₀: 32 μM

CDK2, IC₅₀: 7.1 μM

99.81%

TL12-186

cdk2/cyclin A, IC₅₀: 73 nM

CDK9/cyclinT1, IC₅₀: 55 nM

99.63%

Romaciclib monohydrochloride

CDK8/CycC, IC₅₀: 4.4 nM

CDK9/cycT, IC₅₀: 1070 nM

CDK19/CycC, IC₅₀: 10.4 nM

99.29%

Mevociclib

CDK7

99.27%

CGP60474

CDK1-Cyclin B, IC₅₀: 26 nM

CDK2/cyclinE, IC₅₀: 3 nM
cdk2/cyclin A, IC₅₀: 4 nM

CDK4/cyclin D, IC₅₀: 216 nM

Cdk5/p25, IC₅₀: 10 nM

CDK7/cyclin H, IC₅₀: 200 nM

CDK9/cycT, IC₅₀: 13 nM

99.23%

(E/Z)-Zotiraciclib

CDK2, IC₅₀: 13 nM

99.96%

Nimbolide

CDK4

CDK6

99.79%

BSJ-04-132

CDK4/D1, IC₅₀: 50.6 nM

CDK6/D1, IC₅₀: 30 nM

99.07%

BSJ-03-204

CDK4/D1, IC₅₀: 26.9 nM

CDK6/D1, IC₅₀: 10.4 nM

99.76%

XL413 monohydrochloride

Cdc7, IC₅₀: 3.4 nM

99.72%

BSJ-03-123

CDK6

98.12%

PROTAC CDK2/9 Degrader-1

CDK2, DC₅₀: 62 nM

CDK9, DC₅₀: 33 nM

99.85%

NU6300

CDK2

98.44%

FMF-04-159-2

CDK2, IC₅₀: 256 nM (in NanoBRET assay)

CDK14/Cyclin Y, IC₅₀: 39.6 nM (in NanoBRET assay)

99.48%

AUZ 454

CDK2(C118L/A144C), Kd: 9.7 nM
CDK2(A144C), Kd: 15.4 nM
CDK2(C118L), Kd: 18.6 nM
CDK2(WT), Kd: 50 nM
CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM

99.57%

THZ1 Hydrochloride

CDK7, IC₅₀: 3.2 nM

99.06%

Ebvaciclib

CDK2, Ki: 0.09 nM

CDK4, Ki: 0.13 nM

CDK6, Ki: 0.16 nM

99.98%

PF 477736

CDK1, Ki: 9.9 μM

99.21%

CCT-251921

CDK8, IC₅₀: 2.3 nM

CDK19, IC₅₀: 2.6 nM

99.01%

XY028-140

CDK4

CDK6

98.52%

CTX-712

CLK2, IC₅₀: 1.4 nM

98.15%

Cucurbitacin E

cyclin B1/CDC2

99.92%

Roniciclib

Cdk1/cyclin B, IC₅₀: 7 nM

CDK2/cyclinE, IC₅₀: 9 nM

CDK4/cyclin D, IC₅₀: 11 nM

CDK7/Cyclin H/MAT1, IC₅₀: 25 nM

CDK9/cyclinT1, IC₅₀: 5 nM

98.09%

Amantadine hydrochloride

CDK2

≥98.0%

PHA-767491 hydrochloride

CDK1, IC₅₀: 250 nM

CDK2, IC₅₀: 240 nM

CDK5, IC₅₀: 460 nM

CDK9, IC₅₀: 34 nM

99.49%

R547

Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC₅₀: 0.2 nM

CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC₅₀: 0.1 nM
CDK2/cyclinE, IC₅₀: 0.4 nM

CDK3/Cyclin E, IC₅₀: 0.8 nM

CDK4/cyclin D, Ki: 1 nM

CDK5/p35, IC₅₀: 0.1 nM

cdk6/cyclin D3, IC₅₀: 4 nM

CDK7/cyclin H, IC₅₀: 171 nM

99.57%

Senexin A

CDK8, Kd: 0.83 μM
CDK8, IC₅₀: 280 nM

CDK19, Kd: 0.31 μM

99.79%

T025

CLK1, Kd: 4.8 nM
CLK2, Kd: 0.096 nM
CLK3, Kd: 6.5 nM
CLK4, Kd: 0.61 nM

99.64%

CDK2-IN-4

Cdk1/cyclin B, IC₅₀: 86 μM

cdk2/cyclin A, IC₅₀: 44 nM

99.85%

Purvalanol A

cdc2-cyclin B, IC₅₀: 4 nM

cdk2-cyclin E, IC₅₀: 35 nM
cdk2-cyclin A, IC₅₀: 70 nM

cdk4-cyclin D1, IC₅₀: 850 nM

cdk5-p35, IC₅₀: 75 nM

98.30%

BMS-265246

CDK1/cycB, IC₅₀: 6 nM

CDK2/Cyc E, IC₅₀: 9 nM

CDK4/cycD, IC₅₀: 230 nM

98.92%

LDC000067

cdk1-cyclin B1, IC₅₀: 5513 nM

cdk2-cyclin A, IC₅₀: 2441 nM

cdk4-cyclin D1, IC₅₀: 9242 nM

CDK9- Cyclin T1, IC₅₀: 44 nM

99.00%

Asnuciclib

CDK1, IC₅₀: 8.17 nM
CDK1, Ki: 4 nM

CDK2, IC₅₀: 3.27 nM
CDK2, Ki: 3 nM

CDK4, IC₅₀: 8.18 nM

CDK6, IC₅₀: 37.68 nM

CDK7, IC₅₀: 134.26 nM
CDK7, Ki: 91 nM

CDK9, IC₅₀: 5.78 nM
CDK9, Ki: 4 nM

99.76%

THZ2

CDK1, IC₅₀: 96.9 nM

CDK2, IC₅₀: 222 nM

CDK5, IC₅₀: 134 nM

CDK7, IC₅₀: 13.9 nM

CDK8, IC₅₀: 6830 nM

CDK9, IC₅₀: 194 nM

99.03%

Trilaciclib hydrochloride

Cdk4/cyclin D1, IC₅₀: 1 nM

cdk6/cyclin D3, IC₅₀: 4 nM

99.69%

SU9516

CDK1, IC₅₀: 40 nM

CDK2, IC₅₀: 22 nM

CDK4, IC₅₀: 200 nM

99.81%

BS-181 hydrochloride

CDK1/cycB, IC₅₀: 8.1 μM

CDK2/Cyc E, IC₅₀: 0.88 μM

CDK4/Cyc D1, IC₅₀: 33 μM

CDK5/p35NCK, IC₅₀: 3 μM

CDK6/cycD1, IC₅₀: 47 μM

CDK7/CycH/MAT1, IC₅₀: 0.021 μM

CDK9/cycT, IC₅₀: 4.2 μM

99.80%

Abemaciclib metabolite M2

CDK4, IC₅₀: 1.2 nM

CDK6, IC₅₀: 1.3 nM

99.94%

Senexin B

CDK8, Kd: 140 nM

CDK19, Kd: 80 nM

99.72%

Milciclib

cyclin B/CDK1, IC₅₀: 398 nM

cyclin A/CDK2, IC₅₀: 45 nM
cyclin E/CDK2, IC₅₀: 363 nM

cyclin D1/CDK4, IC₅₀: 160 nM

cyclin H/CDK7, IC₅₀: 150 nM

99.90%

(R)-CR8 trihydrochloride

CDK1/cyclinB1, IC₅₀: 0.09 μM

cdk2/cyclin A, IC₅₀: 0.072 μM
CDK2/cyclinE, IC₅₀: 0.041 μM

Cdk5/p25, IC₅₀: 0.11 μM

CDK7/cyclin H, IC₅₀: 1.1 μM

CDK9/Cyclin T, IC₅₀: 0.18 μM

98.95%

Narazaciclib

Cdk4/cyclin D1, IC₅₀: 3.9 nM

CDK6/cyclinD1, IC₅₀: 9.82 nM

99.12%

Lerociclib dihydrochloride

CDK1/cyclinB1, IC₅₀: 2.4 μM

cdk2/cyclin A, IC₅₀: 1.5 μM
CDK2/cyclinE, IC₅₀: 3.6 μM

Cdk4/cyclin D1, IC₅₀: 1 nM

CDK5/p35, IC₅₀: 832 nM
Cdk5/p25, IC₅₀: 1.2 μM

cdk6/cyclin D3, IC₅₀: 2 nM

CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM

CDK9/Cyclin T, IC₅₀: 28 nM

98.11%

GFB-12811

CDK2/CycA, IC₅₀: 211 nM

Cdk5/p25, IC₅₀: 2.3 nM

CDK6, IC₅₀: 3197 nM

CDK7/Cyclin H/MAT1, IC₅₀: 718 nM

CDK9/CycT1, IC₅₀: 894 nM

98.04%

TC11

CDK1

99.55%

JSH-150

Cdk1/cyclin B, IC₅₀: 1.34 μM

cdk2/cyclin A, IC₅₀: 2.86 μM

Cdk5/p25, IC₅₀: 4.64 μM

CDK7/Cyclin H/MNAT1, IC₅₀: 1.72 μM

CDK9/cyclinT1, IC₅₀: 1 nM

CDK14/Cyclin Y, IC₅₀: 1.68 μM

CDK16/Cyclin Y, IC₅₀: 292 nM

98.66%

Purvalanol B

cdc2/cyclin B, IC₅₀: 6 nM

cdk2/cyclin A, IC₅₀: 6 nM
CDK2/cyclinE, IC₅₀: 9 nM

CDK5/p35, IC₅₀: 6 nM

XL413

Cdc7, IC₅₀: 3.4 nM

99.76%

Atuveciclib

CDK1/CycB(h), IC₅₀: 1100 nM

CDK2/CycE(h), IC₅₀: 1000 nM

CDK3/CycE(h), IC₅₀: 890 nM

CDK5/p35(h), IC₅₀: 1600 nM

CDK9/CycT1, IC₅₀: 13 nM
CDK9/CycT1(h), IC₅₀: 6 nM

99.80%

CP-10

CDK6, DC₅₀: 2.1 nM

98.41%

CLK1-IN-1

CLK1, IC₅₀: 2 nM

98.79%

Abemaciclib metabolite M18 hydrochloride

CDK4

CDK6

98.18%

CDK12-IN-3

CDK12, IC₅₀: 491 nM

99.86%

CDK5 inhibitor 20-223

CDK2, IC₅₀: 6.0 nM

CDK5, IC₅₀: 8.8 nM

99.78%

LY2857785

CDK7, IC₅₀: 0.246 μM

CDK8, IC₅₀: 0.016 μM

CDK9, IC₅₀: 0.011 μM

99.92%

MC180295

CDK1-Cyclin B, IC₅₀: 138 nM

cdk2-cyclin A, IC₅₀: 233 nM
cdk2-cyclin E, IC₅₀: 367 nM

CDK3-Cyclin E, IC₅₀: 399 nM

CDK4-Cyclin D, IC₅₀: 112 nM

cdk5-p35, IC₅₀: 159 nM
cdk5-p25, IC₅₀: 186 nM

cdk6-cyclin D3, IC₅₀: 712 nM

CDK7-CycH/MAT1, IC₅₀: 555 nM

CDK9- Cyclin T1, IC₅₀: 5 nM

98.89%

PROTAC CDK9 Degrader-1

CDK9

98.03%

Dalpiciclib

CDK4, IC₅₀: 12.4 nM

CDK6, IC₅₀: 9.9 nM

99.70%

RGB-286638

cyclin B1-CDK1, IC₅₀: 2 nM

cyclin E-CDK2, IC₅₀: 3 nM

cyclin E-CDK3, IC₅₀: 5 nM

cyclin D1-CDK4, IC₅₀: 4 nM

p35-CDK5, IC₅₀: 5 nM

cyclin D3-CDK6, IC₅₀: 55 nM

cyclin H-CDK7, IC₅₀: 44 nM

T1-CDK9, IC₅₀: 1 nM

99.70%

CKI-7 free base

Cdc7

99.80%

BRD6989

CDK8, IC₅₀: ~200 nM
recombinant CDK8, IC₅₀: ~0.5 μM

recombinant CDK19, IC₅₀: >30 μM

99.56%

PHA-793887

Cdk1/cyclin B, IC₅₀: 60 nM

cdk2/cyclin A, IC₅₀: 8 nM
CDK2/cyclinE, IC₅₀: 8 nM

Cdk4/cyclin D1, IC₅₀: 62 nM

Cdk5/p25, IC₅₀: 5 nM

CDK7/cyclin H, IC₅₀: 10 nM

CDK9/cyclinT1, IC₅₀: 138 nM

99.25%

SEL120-34A hydrochloride

CDK8/CycC, IC₅₀: 4.4 nM

CDK9/cycT, IC₅₀: 1070 nM

CDK19/CycC, IC₅₀: 10.4 nM

99.98%

Voruciclib

CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM

CDK4/Cyc D1, Ki: 3.96 nM

CDK6/cycD1, Ki: 2.92 nM

CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM

99.77%

PROTAC CDK12/13 Degrader-1 TFA

CDK12, DC₅₀: 2.2 nM

CDK13, DC₅₀: 2.1 nM

98.37%

Alsterpaullone

Cdk1/cyclin B, IC₅₀: 35 nM

cdk2/cyclin A, IC₅₀: 15 nM
CDK2/Cyc E, IC₅₀: 200 nM

CDK5/p35, IC₅₀: 40 nM

99.85%

YX-2-107

CDK6, IC₅₀: 4.4 nM

99.79%

Thiabendazole

CCNE1

CDK2

99.77%

CDK12-IN-2

CDK2, IC₅₀: >100 μM

CDK7, IC₅₀: >10 μM
CDK7, IC₅₀: >10 μM

CDK9, IC₅₀: 16 μM

CDK12, IC₅₀: 52 nM

99.36%

FN-1501

cdk2/cyclin A, IC₅₀: 2.47 nM

Cdk4/cyclin D1, IC₅₀: 0.85 nM

CDK6/cyclinD1, IC₅₀: 1.96 nM

99.08%

Riviciclib hydrochloride

CDK1-Cyclin B, IC₅₀: 0.079 μM

cdk2-cyclin A, IC₅₀: 0.224 μM
cdk2-cyclin E, IC₅₀: 2.500 μM

cdk4-cyclin D1, IC₅₀: 0.063 μM

cdk6-cyclin D3, IC₅₀: 0.396 μM

CDK9- Cyclin T1, IC₅₀: 0.020 μM
CDK9-cyclin H, IC₅₀: 2.900 μM

99.08%

KH-CB19

CLK1, IC₅₀: 19.7 nM
CLK3, IC₅₀: 530 nM

99.31%

ML167

CDK3, IC₅₀: ＞10000 nM

CLK4, IC₅₀: 136 nM
CLK1, IC₅₀: 1522 nM
CLK2, IC₅₀: 1648 nM

98.62%

Bisindolylmaleimide X hydrochloride

CDK2, IC₅₀: 200 nM

98.90%

XY028-133

CDK4

CDK6

98.62%

CC-671

CLK2, IC₅₀: 0.006 μM

99.06%

AZ5576

CDK9, : <5 nM

99.88%

β-catenin-IN-3

Cdk4/cyclin D1

Palbociclib-d₈

Cdk4/cyclin D3, IC₅₀: 9 nM
Cdk4/cyclin D1, IC₅₀: 11 nM

Cdk6/cyclin D2, IC₅₀: 16 nM

99.84%

JH-XI-10-02

CDK8, IC₅₀: 159 nM

99.82%

(-)-Enitociclib

CDK9

99.85%

CDK12-IN-E9

cdk2/cyclin A, IC₅₀: 932 nM

CDK7/Cyclin H/MNAT1, IC₅₀: 1210 nM

CDK9/cyclinT1, IC₅₀: 23.9 nM

99.97%

Dalpiciclib hydrochloride

CDK4, IC₅₀: 12.4 nM

CDK6, IC₅₀: 9.9 nM

98.22%

CDK5-IN-3

CDK2/CycA, IC₅₀: 18 nM

Cdk5/p25, IC₅₀: 0.6 nM

99.49%

CDK9-IN-1

CDK9/CycT1, IC₅₀: 39 nM

98.52%

CDK9-IN-2

CDK9, IC₅₀: 5 nM (H929 multiple myeloma cell line)

99.37%

YKL-5-124 TFA

CDK2, IC₅₀: 1300 nM

CDK7, IC₅₀: 53.5 nM
CDK7/Mat1/CycH, IC₅₀: 9.7 nM

CDK9, IC₅₀: 3020 nM

99.74%

EHT 5372

CLK1, IC₅₀: 22.8 nM
CLK2, IC₅₀: 88.8 nM
CLK4, IC₅₀: 59.0 nM

98.12%

NU6102

Cdk1/cyclin B, IC₅₀: 9.5 nM

CDK2/cyclin A3, IC₅₀: 5.4 nM

CDK4, IC₅₀: 1.6 μM

99.23%

HS-243

CLK4, IC₅₀: 662 nM

99.95%

RSS0680

CDK1

CDK2

CDK4

CDK6

CDK16/Cyclin Y

98.03%

MeBIO

Cdk1/cyclin B, IC₅₀: 55 μM

Cdk5/p25, IC₅₀: >100 μM

≥98.0%

AMG 925

CDK1, IC₅₀: 1.9 μM

CDK2, IC₅₀: 375 nM

CDK4, IC₅₀: 3 nM

CDK6, IC₅₀: 8 nM

98.71%

Tambiciclib

CDK9

99.21%

Samuraciclib hydrochloride dihydrate

CDK1, IC₅₀: 1.8 μM

CDK2, IC₅₀: 578 nM

CDK4, IC₅₀: 49 μM

CDK5, IC₅₀: 9.4 μM

CDK6, IC₅₀: 31 μM

CDK7, IC₅₀: 41 nM

CDK9, IC₅₀: 1.2 μM

99.08%

XO44

CDK1

CDK2

CDK4

99.38%

Abemaciclib metabolite M20

CDK4

CDK6

LY3177833

Cdc7, IC₅₀: 3.3 nM

99.48%

CDK-IN-2

CDK9/cyclinT1, IC₅₀: 8 nM

98.97%

CDK2-IN-3

CDK2, IC₅₀: 60 nM

Garcinone C

CDK7

99.66%

LDC4297

CDK7, IC₅₀: 0.13 nM

98.25%

NU6140

CDK1-Cyclin B, IC₅₀: 6.6 μM

cdk2-cyclin A, IC₅₀: 0.41 μM

CDK4-Cyclin D, IC₅₀: 5.5 μM

cdk5-p25, IC₅₀: 15 μM

cdk7-cyclin H, IC₅₀: 3.9 μM

99.07%

DS96432529

CDK8

99.93%

Avotaciclib

CDK1

99.72%

CDK9 inhibitor HH1

CDK9

99.56%

K00546

Cdk1/cyclin B, IC₅₀: 0.6 nM

cdk2/cyclin A, IC₅₀: 0.5 nM

CLK1, IC₅₀: 8.9 nM
CLK3, IC₅₀: 29.2 nM

98.08%

FIT-039

CDK9/cyclinT1, IC₅₀: 5.8 μM

99.56%

JH-XVI-178

CDK8, IC₅₀: 1 nM

CDK19, IC₅₀: 2 nM

98.87%

Olomoucine

cdk2-cyclin A, IC₅₀: 7 μM
cdk2-cyclin E, IC₅₀: 7 μM

cdk5-p35, IC₅₀: 25 μM

99.87%

KB-0742

CDK9/cyclinT1, IC₅₀: 6 nM

99.38%

BSJ-01-175

CDK12

CDK13

99.45%

Ipivivint

CDK2, EC₅₀: 1 nM

CDK3, EC₅₀: 7 nM

99.95%

CDK4/6-IN-2

CDK4, IC₅₀: 2.7 nM

CDK6, IC₅₀: 16 nM

99.82%

GW8510

CDK2

CDK5

99.64%

CDK4/6-IN-15

CDK2, IC₅₀: 3.335 μM

CDK4, IC₅₀: 3 nM

CDK6, IC₅₀: 0.279 μM

99.32%

DB0614

CDK6

CDK16/Cyclin Y

98.80%

CDK9-IN-7

CDK4/cyclin D, IC₅₀: 148 nM

CDK6/cyclinD, IC₅₀: 145 nM

CDK9/cyclinT1, IC₅₀: 11 nM

98.05%

LL-K8-22

CDK8, DC₅₀: 2.52 μM

99.76%

Cimpuciclib tosylate

CDK4, IC₅₀: 0.49 nM

CDK6, IC₅₀: 9.56 nM

99.16%

GSK-3 inhibitor 3

CDK2, IC₅₀: 0.22 μM

CDK5, IC₅₀: 1.3 μM

98.72%

Senexin C

CDK8/CycC, IC₅₀: 3.6 nM
CDK8/CycC, Kd: 1.4 nM

CDK19/CycC, Kd: 2.9 nM

98.06%

CDK8-IN-11

CDK8, IC₅₀: 46 nM

98.20%

CDK8-IN-13

CDK8, IC₅₀: 51.9 nM

99.14%

Casein Kinase inhibitor A86

CDK7, Kd: 0.31 nM

CDK9, Kd: 5.4 nM

99.26%

RGB-286638 free base

cyclin B1-CDK1, IC₅₀: 2 nM

cyclin E-CDK2, IC₅₀: 3 nM

cyclin E-CDK3, IC₅₀: 5 nM

cyclin D1-CDK4, IC₅₀: 4 nM

p35-CDK5, IC₅₀: 5 nM

cyclin D3-CDK6, IC₅₀: 55 nM

cyclin H-CDK7, IC₅₀: 44 nM

T1-CDK9, IC₅₀: 1 nM

98.07%

AT7519 Hydrochloride

Cdk1/cyclin B, IC₅₀: 210 nM

cdk2/cyclin A, IC₅₀: 47 nM

Cdk4/cyclin D1, IC₅₀: 100 nM

CDK5/p35, IC₅₀: 13 nM

cdk6/cyclin D3, IC₅₀: 170 nM

CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM

CDK9/Cyclin T, IC₅₀: 10 nM

99.42%

Atuveciclib Racemate

CDK9

98.48%

CDK9-IN-8

CDK9, IC₅₀: 12 nM

99.65%

CDK9-IN-13

CDK1, IC₅₀: 0.14 μM

CDK2, IC₅₀: 0.72 μM

CDK7, IC₅₀: 0.40 μM

CDK9, IC₅₀: <3 nM

CDK12, IC₅₀: 0.055 μM

99.94%

TP-1287

CDK9

LDC4297 hydrochloride

CDK7, IC₅₀: 0.13 nM

98.23%

NSC 625987

CDK4/D1, IC₅₀: 0.2 μM

98.58%

AZD5597

CDK1, IC₅₀: 2 nM

CDK2, IC₅₀: 2 nM

98.09%

CK7

CDK2

CDK9

99.72%

CDK1-IN-2

CDK1, IC₅₀: 5.8 μM

Manzamine A hydrochloride

CDK5, IC₅₀: 1.5 μM

99.66%

DB1113

CDK4

CDK11B

99.28%

NU2058

CDK1, IC₅₀: 26 μM

CDK2, IC₅₀: 17 μM
CDK2, Ki: 12 μM

99.66%

Longdaysin

CDK7, IC₅₀: 29 μM

99.83%

Butyrolactone I

CDK1

98.03%

Avotaciclib trihydrochloride

CDK1

99.75%

Samuraciclib hydrochloride hydrate

CDK1, IC₅₀: 1.8 μM

CDK2/cycE1, IC₅₀: 578 nM

CDK4, IC₅₀: 49 μM

CDK5, IC₅₀: 9.4 μM

CDK6, IC₅₀: 34 μM

CDK7/CycH/MAT1, IC₅₀: 41 nM

CDK9, IC₅₀: 1.2 μM

99.88%

(E/Z)-Zotiraciclib hydrochloride

CDK2

99.90%

BGG463

CDK2

≥98.0%

Desmethylglycitein

CDK1

CDK2

98.98%

GW297361

yeast Cdk1, IC₅₀: 20 nM
human CDK1, IC₅₀: 30 nM

human CDK2, IC₅₀: 1.9 nM

human CDK4, IC₅₀: 300 nM

human CDK9, IC₅₀: 10 nM

yeast Pho85, IC₅₀: 400 nM

98.13%

NVP-LCQ195

Cdk1/cyclin B, IC₅₀: 2 nM

cdk2/cyclin A, IC₅₀: 2 nM
CDK2/cyclinE, IC₅₀: 5 nM

CDK3/Cyclin E, IC₅₀: 42 nM

Cdk5/p25, IC₅₀: 1 nM
CDK5/p35, IC₅₀: 1 nM

cdk6/cyclin D3, IC₅₀: 187 nM

CDK7/Cyclin H/MAT1, IC₅₀: 3564 nM

CDK9/cyclinT1, IC₅₀: 15 nM

98.81%

Ca2+ channel agonist 1

CDK2, EC₅₀: 3.34 μM

99.71%

CA224

cdk2-cyclin A, IC₅₀: 521 μM

cdk4-cyclin D1, IC₅₀: 6.2 μM

99.94%

CAN508

Cdk1/cyclin B, IC₅₀: 44 μM

CDK2/cyclinE, IC₅₀: 20 μM
cdk2/cyclin A, IC₅₀: 69 μM

Cdk4/cyclin D1, IC₅₀: 13.5 μM

CDK7/cyclin H, IC₅₀: 26 μM

CDK9/cyclinT1, IC₅₀: 0.35 μM

99.59%

AS2863619 free base

CDK8, IC₅₀: 0.61 nM

CDK19, IC₅₀: 4.28 nM

99.87%

BI-1622

CDK11B

98.97%

(E/Z)-Zotiraciclib citrate

CDK2

98.06%

NU6027

CDK1, Ki: 2.5 μM

CDK2, Ki: 1.3 μM

99.04%

CDK8/19-IN-1

CDK8/CycC, IC₅₀: 0.46 nM

CDK9, IC₅₀: 270 nM

CDK19/CycC, IC₅₀: 0.99 nM

98.03%

CDK9-IN-11

CDK9

PROTAC CDK12/13 Degrader-1

CDK12, DC₅₀: 2.2 nM

CDK13, DC₅₀: 2.1 nM

98.01%

NecroIr1

CDK4

98.02%

CLK1-IN-3

CLK1, IC₅₀: 5 nM
CLK2, IC₅₀: 42 nM
CLK4, IC₅₀: 108 nM

98.03%

ABC1183

CDK9- Cyclin T1, IC₅₀: 321 nM

99.19%

ON-013100

Cdk4/cyclin D1

98.66%

Ribociclib succinate hydrate

CDK4, IC₅₀: 10 nM

CDK6, IC₅₀: 39 nM

99.96%

HTH-01-091

CDK7, IC₅₀: 1230 nM

98.64%

CDK1-IN-1

CDK1/cycB, IC₅₀: 161.2 nM

99.33%

HEMTAC CDK4/6 degrader 1

CDK4

CDK6

98.18%

Lacto-N-fucopentaose I

CDK2/cyclinE

99.92%

CDK12-IN-5

CDK2/cyclinE, IC₅₀: 173 μM

CDK9/cyclinT1, IC₅₀: 127 μM

CDK12, IC₅₀: 23.9 nM

99.01%

THZ1-R

CDK7, IC₅₀: 146 nM

98.12%

7BIO

CDK5

99.20%

PNU112455A hydrochloride

CDK2, Km: 3.6 μM

CDK5, Km: 3.2 μM

99.56%

CDK8-IN-1

CDK8, IC₅₀: 3 nM

99.77%

Voruciclib hydrochloride

CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM

CDK4/Cyc D1, Ki: 3.96 nM

CDK6/cycD1, Ki: 2.92 nM

CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM

99.23%

CDDD11-8

CDK9, Ki: 8 nM

99.62%

CDK7-IN-21

CDK7

Cdk1/2 Inhibitor III

Cdk1/cyclin B, IC₅₀: 2.1 μM

99.69%

Vanicoside B

CDK3

99.82%

Isosilybin B

CDK2

CDK4

99.32%

CDK2-IN-30

CDK2, IC₅₀: ≤ 20 nM

Ryuvidine

CDK4, IC₅₀: 6.0 μM

99.40%

CDK9-IN-10

CDK9

98.09%

CDK9-IN-12

CDK9/cyclinT1, IC₅₀: 5.41 nM

99.65%

PHA-767491

CDK1, IC₅₀: 250 nM

CDK2, IC₅₀: 240 nM

CDK5, IC₅₀: 460 nM

CDK9, IC₅₀: 34 nM

99.85%

(R)-DRF053 dihydrochloride

CDK1/cyclinB1, IC₅₀: 220 nM

Cdk5/p25, IC₅₀: 80 nM

99.30%

(R)-(+)-O-Demethylbuchenavianine

CDK1, IC₅₀: 1.1 μM

CDK5, IC₅₀: 0.95 μM

98.67%

PNU-292137

CDK1/cyclinB, IC₅₀: 270 nM

CDK2/cyclinA, IC₅₀: 37 nM
CDK2/cyclin E, IC₅₀: 92 nM

CDK4/cyclinD1, IC₅₀: >10000 nM

Cdk5/p25, IC₅₀: 114 nM

99.93%

Lerociclib

CDK1/cyclinB1, IC₅₀: 2.4 μM

cdk2/cyclin A, IC₅₀: 1.5 μM
CDK2/cyclinE, IC₅₀: 3.6 μM

Cdk4/cyclin D1, IC₅₀: 1 nM

CDK5/p35, IC₅₀: 0.832 μM
Cdk5/p25, IC₅₀: 1.2 μM

cdk6/cyclin D3, IC₅₀: 2 nM

CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM

CDK9/Cyclin T, IC₅₀: 28 nM

98.35%

CDK1-IN-6

CDK1

99.96%

NSC693868

Cdk1/cyclin B, IC₅₀: 600 nM

Cdk5/p25, IC₅₀: 400 nM

≥99.0%

CPD-39

CDK4

YKL-1-116

CDK7

98.67%

RGB-286147

CDK1/cyclinB, IC₅₀: 48 nM

CDK2/E, IC₅₀: 15 nM

CDK4/D1, IC₅₀: 839 nM

cdk6/cyclin D3, IC₅₀: 232 nM

98.60%

NecroIr2

CDK4

98.99%

BS-194

CDK1, IC₅₀: 30 nM

CDK2, IC₅₀: 3 nM

CDK5, IC₅₀: 30 nM

CDK7, IC₅₀: 250 nM

CDK9, IC₅₀: 90 nM

99.36%

CGP-82996

CDK1/cyclinB, IC₅₀: >100 μM

CDK2/cyclinA, IC₅₀: >50 μM
CDK2/cyclin E, IC₅₀: >50 μM

Cdk4/cyclin D1, IC₅₀: 1.5 μM
CDK4/cyclin D2, IC₅₀: >50 μM

CDK5/p35, IC₅₀: 25 μM

CDK6/cyclinD1, IC₅₀: 5.6 μM
Cdk6/cyclin D2, IC₅₀: >50 μM

98.12%

5-Iodo-indirubin-3'-monoxime

Cdk1/cyclin B, IC₅₀: 25 nM

Cdk5/p25, IC₅₀: 20 nM

99.50%

CDK7-IN-4

CDK7

98.87%

PROTAC CDK4/6 degrader 1

CDK4, DC₅₀: 10.5 nM

CDK6, DC₅₀: 2.5 nM

98.88%

KH-CB20

CLK1, IC₅₀: 16.5 nM
CLK3, IC₅₀: 488 nM

99.80%

MU1210

CLK1, IC₅₀: 8 nM
CLK2, IC₅₀: 20 nM
CLK4, IC₅₀: 12 nM

99.50%

TMX-2039

CDK1, IC₅₀: 2.6 nM

CDK2, IC₅₀: 1.0 nM

CDK4, IC₅₀: 52.1 nM

CDK5, IC₅₀: 0.5 nM

CDK6, IC₅₀: 35 nM

CDK7, IC₅₀: 32.5 nM

CDK9, IC₅₀: 25 nM

99.42%

CDK9-IN-14

CDK9, IC₅₀: 6.92 nM

99.91%

CDK7-IN-1

CDK7, IC₅₀: 100 nM

98.91%

(S)-LY3177833 hydrate

Cdc7

BS-181

CDK1/cycB, IC₅₀: 8.1 μM

CDK2/Cyc E, IC₅₀: 0.88 μM

CDK4/Cyc D1, IC₅₀: 33 μM

CDK5/p35NCK, IC₅₀: 3 μM

CDK6/cycD1, IC₅₀: 47 μM

CDK7/CycH/MAT1, IC₅₀: 0.021 μM

CDK9/cycT, IC₅₀: 4.2 μM

98.10%

IV-361

CDK2, Ki: ≥1000 nM

CDK7, Ki: ≤50 nM

99.60%

AT7519 TFA

Cdk1/cyclin B, IC₅₀: 210 nM

cdk2/cyclin A, IC₅₀: 47 nM

Cdk4/cyclin D1, IC₅₀: 100 nM

CDK5/p35, IC₅₀: 13 nM

cdk6/cyclin D3, IC₅₀: 170 nM

CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM

CDK9/Cyclin T, IC₅₀: 10 nM

LY3177833 monhydrate

Cdc7, IC₅₀: 3.3 nM

99.76%

CDK2-IN-22

CDK2, IC₅₀: 64.42 nM

98.64%

PROTAC CDK9 degrader-9

CDK9

98.09%

CDK8 ligand 1

CDK8

CDK2 degrader 4

CDK2

YJ9069

CDK12

CDK13

PT-262

CDK2

99.21%

CDK2/4/6-IN-2

CDK2

CDK4

CDK6

Bohemine

CDK2/cyclinE, IC₅₀: 4.6 μM
cdk2/cyclin A, IC₅₀: 83 μM

CDK9/cyclinT1, IC₅₀: 2.7 μM

98.93%

PROTAC CDK9 degrader-2

CDK9, IC₅₀: 17 μM (MCF-7 cells)

(E/Z)-BIO-acetoxime

CDK1/cyclinB, IC₅₀: 63 μM

CDK2/cyclinA, IC₅₀: 4.3 μM

Cdk5/p25, IC₅₀: 2.4 μM

CDK1/Cyc B-IN-1

CDK1-Cyclin B, IC₅₀: 97 nM

98.47%

CDK2 degrader 3

CDK2

CDK5-IN-1

CDK5

98.47%

CDK12-IN-6

CDK2/cyclinE, IC₅₀: >20 μM

CDK9/cyclinT1, IC₅₀: >20 μM

CDK12, IC₅₀: 1.19 μM

98.09%

Akt1&PKA-IN-1

CDK2, IC₅₀: 9.8 μM

CDK8-IN-12

CDK8, Ki: 14 nM

99.74%

JSH-009 dimaleate

CDK1/cyclinB, IC₅₀: 5410 nM

CDK2/cyclinA, IC₅₀: 6850 nM

CDK3/cyclin E1, IC₅₀: >10 (Pan)

Cdk5/p25, IC₅₀: 6950 nM

CDK7/Cyclin H/MNAT1, IC₅₀: 3700 nM

CDK8/cyclin C, IC₅₀: >10 (Pan)

CDK9/cyclinT1, IC₅₀: 0.928 nM

CDK11, IC₅₀: >10 (Pan)

CDK14/Cyclin Y, IC₅₀: 2710 nM

CDK16/Cyclin Y, IC₅₀: 195 nM

CLK1/2-IN-1

CLK1, IC₅₀: 16 nM
CLK2, IC₅₀: 45 nM

99.87%

AMG 925 (HCl)

CDK1, IC₅₀: 1.9 μM

CDK2, IC₅₀: 375 nM

CDK4, IC₅₀: 3 nM

CDK6, IC₅₀: 8 nM

GSK-3 inhibitor 4

CDK2, IC₅₀: 0.47 μM

CDK5, IC₅₀: 0.68 μM

98.77%

Akt1&PKA-IN-2

CDK2^a, IC₅₀: 0.69 μM

Manzamine A

CDK5, IC₅₀: 1.5 μM

SEL120-34A

CDK8/CycC, IC₅₀: 4.4 nM

CDK9/cycT, IC₅₀: 1070 nM

CDK19/CycC, IC₅₀: 10.4 nM

CDK2 degrader 5

CDK2

Abemaciclib metabolite M18

CDK4

CDK6

Abemaciclib metabolite M20-d₈

CDK4

CDK6

99.26%

CDD-2807

CLK4, IC₅₀: 85 nM
CLK2, IC₅₀: 101 nM
CLK1, IC₅₀: 116 nM

JA397

CDK14/Cyclin Y, EC₅₀: 27.1 nM

CDK16/Cyclin Y, EC₅₀: 39.0 nM

Palbociclib dihydrochloride

Cdk4/cyclin D3, IC₅₀: 9 nM
Cdk4/cyclin D1, IC₅₀: 11 nM

Cdk6/cyclin D2, IC₅₀: 16 nM

Palbociclib orotate

Cdk4/cyclin D3, IC₅₀: 9 nM
Cdk4/cyclin D1, IC₅₀: 11 nM

Cdk6/cyclin D2, IC₅₀: 16 nM

Samuraciclib

CDK1, IC₅₀: 1.8 μM

CDK2/cycE1, IC₅₀: 578 nM

CDK4, IC₅₀: 49 μM

CDK5, IC₅₀: 9.4 μM

CDK6, IC₅₀: 34 μM

CDK7/CycH/MAT1, IC₅₀: 41 nM

CDK9, IC₅₀: 1.2 μM

CDK1-IN-5

CDK1, IC₅₀: 42.19 nM

CDK2, IC₅₀: 188.71 nM

CDK5, IC₅₀: 354.15 nM

Cimpuciclib

CDK4, IC₅₀: 0.49 nM

CDK6, IC₅₀: 9.56 nM

CDK1-IN-3

CDK1, IC₅₀: 36.8 nM

CDK2, IC₅₀: 305.17 nM

CDK5, IC₅₀: 369.37 nM

OTS964

CDK11B, Kd: 40 nM

ZLMT-12

CDK2, IC₅₀: 0.011 μM

CDK9, IC₅₀: 0.002 μM

CDK7-IN-2 hydrochloride hydrate

CDK7

BS-181 dihydrochloride

CDK2, IC₅₀: 880 nM

CDK5, IC₅₀: 3000 nM

CDK7, IC₅₀: 21 nM

CDK9, IC₅₀: 4200 nM

CDK4/6-IN-3

CDK1, Ki: 110 nM

CDK4, Ki: 0.3 nM

CDK6, Ki: 2.2 nM

FN-1501-propionic acid

CDK2

CDK9

CDK9-IN-9

CDK2, IC₅₀: 155 nM

CDK9, IC₅₀: 1.8 nM

CDK7-IN-11

CDK7, IC₅₀: 4.2 nM

HDAC1/2 and CDK2-IN-1

CDK2, IC₅₀: 0.80 nM

Riviciclib

CDK1-Cyclin B, IC₅₀: 0.079 μM

cdk2-cyclin A, IC₅₀: 0.224 μM
cdk2-cyclin E, IC₅₀: 2.540 μM

cdk4-cyclin D1, IC₅₀: 0.063 μM

cdk6-cyclin D3, IC₅₀: 0.396 μM

CDK9- Cyclin T1, IC₅₀: 0.020 μM
CDK9-cyclin H, IC₅₀: 2.900 μM

CDK6/9-IN-1

CDK6, IC₅₀: 40.5 nM

CDK9, IC₅₀: 39.5 nM

Senexin A hydrochloride

CDK8, IC₅₀: 280 nM
CDK8, Kd: 0.83 μM

CDK19, Kd: 0.31 μM

Amantadine sulfate

CDK2

CDK7-IN-30

CDK1, IC₅₀: >10000.00 nM

CDK2, IC₅₀: 734.55 nM

CDK3, IC₅₀: 370.40 nM

CDK4, IC₅₀: 644.80 nM

CDK5, IC₅₀: 3678.50 nM

CDK6, IC₅₀: 1345.50 nM

CDK7, IC₅₀: 7.21 nM

CDK9, IC₅₀: 704.3 nM

CDK2-IN-41

CDK2

CDK7-IN-6

CDK7, IC₅₀: ≤100 nM

CDK2/4-IN-1

CDK2

CDK4

CDK7-IN-16

CDK7, IC₅₀: 1~10 nM

CDK8-IN-6

CDK8, Kd: 13 nM

Haspin-IN-2

CLK1, IC₅₀: 445 nM

CDK4/6-IN-18

CDK4

CDK6

CDK4/9-IN-1

CDK4, IC₅₀: 23 nM

CDK9, IC₅₀: 12 nM

(S)-LY3177833

Cdc7

CDK4/6-IN-23

CDK6, IC₅₀: 11 nM

CKI-7

Cdc7

CDK4/6-IN-12

CDK4, IC₅₀: 592.3 nM

CDK6, IC₅₀: 3090 nM

CDK8-IN-17

CDK8, IC₅₀: 9 nM

CDK8/19-IN-3

CDK8

CDK19

CDK2-IN-12

CDK2, IC₅₀: 11.6 μM

CDK9, IC₅₀: >12.5 μM

CDK7-IN-10

CDK7, IC₅₀: ＜100 nM

HDAC1/CDK7-IN-1

CDK7, IC₅₀: 893 nM

P-gp/CDK2-IN-1

CDK2

CDK4/6-IN-7

CDK4, IC₅₀: 1.58 nM

CDK6, IC₅₀: 4.09 nM

Multi-kinase-IN-4

CDK2, IC₅₀: 2.09 μM

Cdc7-IN-15

Cdc7

CDKI-83

CDK1/B, Ki: 72 nM

CDK2/E, Ki: 232 nM

CDK4/D, Ki: 290 nM

CDK7/H, Ki: 405 nM

CDK9/T1, Ki: 21 nM

Aloisine A

CDK1/cyclinB, IC₅₀: 0.15 μM

CDK2/cyclinA, IC₅₀: 0.12 μM
CDK2/cyclinE, IC₅₀: 0.4 μM

CDK5/p35, IC₅₀: 0.16 μM

CDK7-IN-32

CDK7

CDK9-IN-28

CDK9/cyclinT1

LZ9

CDK1
cyclin B1/CDC2

CLK1/4-IN-1

CLK1, IC₅₀: 9.7 nM
CLK4, IC₅₀: 6.6 nM

CP-07

CDK9

Carbonic anhydrase inhibitor 14

CDK2, IC₅₀: 20.3 μM

CDK4/6-IN-21 maleate

CDK4, IC₅₀: 3.88 nM

CDK6, IC₅₀: 3.31 nM

CDK4/6-IN-20

CDK4, IC₅₀: 1.9 nM

CDK6, IC₅₀: 14.2 nM

Wogonin (Standard)

CDK8

ALK-IN-29

CDK2

CDK2/4/6-IN-1

CDK2, IC₅₀: 2.5 nM

CDK4, IC₅₀: 23.7 nM

CDK6, IC₅₀: 44.3 nM

PARP1/CDK12-IN-1

CDK12, IC₅₀: 285 nM

CDK5-IN-4

CDK2, IC₅₀: 6.24 ± 2.8 μM

CDK5, IC₅₀: 9.8 ± 2.29 μM

CDK9, IC₅₀: 1.76 ± 0.3 μM

CDK9-IN-24

CDK9

TMX-3013

CDK1, IC₅₀: 0.9 nM

CDK2, IC₅₀: <0.5 nM

CDK4, IC₅₀: 24.5 nM

CDK5, IC₅₀: 0.5 nM

CDK6, IC₅₀: 15.6 nM

XL413 hydrochloride

Cdc7, IC₅₀: 3.4 nM

SLM6

CDK9/cyclinT1, IC₅₀: 133 nM

CDK2-IN-8

CDK2, IC₅₀: 1.74 μM

CDK9-IN-33

CDK2, IC₅₀: 316.30 nM

CDK4, IC₅₀: 1771.00 nM

CDK6, IC₅₀: >10000 nM

CDK7, IC₅₀: 160 nM

CDK9, IC₅₀: 17.44 nM

CDK5-IN-2

CDK2/CycA, IC₅₀: 23 nM

Cdk5/p25, IC₅₀: 0.2 nM

GSK3-IN-10

CDK4, IC₅₀: 3800 nM

CLK1, IC₅₀: 620 nM
CLK4, IC₅₀: 760 nM
CLK2, IC₅₀: 800 nM

Cdc7-IN-14

Cdc7, IC₅₀: <1 nM

CDK2-IN-9

CDK2, IC₅₀: 0.63 μM

Cdc7-IN-13

Cdc7, IC₅₀: <1 nM

Fascaplysin

CDK4

CDK9-IN-19

CDK9/cyclinT1, IC₅₀: 2 nM

CDK9-IN-22

cdk2/cyclin A, IC₅₀: 876.2 nM

CDK9/cyclinT1, IC₅₀: 10.4 nM

NUAK1-IN-1

CDK4

SHR5428

CDK1, IC₅₀: >100 μM

CDK2, IC₅₀: 8.99 μM

CDK4, IC₅₀: 3.87 μM

CDK6, IC₅₀: 5.89 μM

CDK7, IC₅₀: 0.005 μM

CDK9, IC₅₀: 8.30 μM

CDK12, IC₅₀: 1.11 μM

CDK2-IN-20

CDK2/cyclinE, IC₅₀: 0.219 μM

CDK4/6-IN-14

CDK1, IC₅₀: >10000 nM

CDK2, IC₅₀: 1045 nM

CDK4, IC₅₀: 10 nM

CDK6, IC₅₀: 16 nM

CDK7, IC₅₀: 2595 nM

CDK9, IC₅₀: 2664 nM

CDK4/6/BRD4-IN-1

CDK4, IC₅₀: 85 nM

CDK6, IC₅₀: 106 nM

AG-012986

Cdk1/cyclin B, Ki: 44 nM

cdk2/cyclin A, Ki: 94 nM

CDK4, Ki: 9.2 nM

CDK5/p35, IC₅₀: 22 nM

CDK9/Cyclin T, IC₅₀: 4 nM

ZDLD20

CDK4/CycD3, IC₅₀: 6.51 μM

99.84%

BLINK11

CDK1/Cly Y, IC₅₀: 39.34 nM

CDK2/ClyA2, IC₅₀: 83.43 nM

CDK5/p35, IC₅₀: 17.09 nM
Cdk5/p25, IC₅₀: 14.69 nM

cdk9-cyclin T, IC₅₀: 83.43 nM

IIIM-290

CDK2/A, IC₅₀: 90 nM

CDK9/T1, IC₅₀: 94 nM

CDK4/6/HDAC-IN-1

CDK1, IC₅₀: 55.6 nM

CDK4, IC₅₀: 7.23 nM

CDK6, IC₅₀: 13.2 nM
CDK6, IC₅₀: 48.38 nM

CDK/HDAC-IN-2

CDK1, IC₅₀: 8.63 nM

CDK2, IC₅₀: 0.30 μM

CDK4, IC₅₀: >1000 nM

CDK6, IC₅₀: >1000 nM

CDK7, IC₅₀: >1000 nM

CDK8-IN-10

CDK8, IC₅₀: 8.25 nM

ZLHQ-5f

CDK2/CycA2, IC₅₀: 0.145 μM

CDK4/6-IN-16

CDK4, IC₅₀: 13 nM

YY173

CDK4, IC₅₀: 7.7 nM

CDK6, IC₅₀: 88 nM

KDM1/CDK1-IN-1

CDK1, IC₅₀: 0.078 ± 2. μM

CDK2-IN-43

Cdk2/cyclin E2, IC₅₀: 6 nM

CDK2-IN-36

CDK2

CDK12/13-IN-2

CDK12, IC₅₀: 15.5 nM

CDK13, IC₅₀: 12.2 nM

CDK2-IN-18

CDK2/cyclinE, IC₅₀: 8 nM

Cdk4/cyclin D1, IC₅₀: 46 nM

CDK2/9-IN-1

CDK2, IC₅₀: 0.004 μM

CDK9, IC₅₀: 0.009 μM

CDK6/PIM1-IN-1

CDK1/cyclinB, IC₅₀: >10 μM

CDK2/cyclinA, IC₅₀: 2.274 μM

CDK3/Cyclin E, IC₅₀: >10 μM

Cdk4/cyclin D1, IC₅₀: 3.6 nM

Cdk5/p25, IC₅₀: >10 μM

CDK6/cyclinD1, IC₅₀: 39 nM

CDK7/Cyclin H/MNAT1, IC₅₀: 393 nM

CDK9/cyclinT1, IC₅₀: 440 nM

CDK12/Cyclin K, IC₅₀: >10 μM

CDK13/Cyclin K, IC₅₀: >10 μM

CDK7-IN-20

CDK1, IC₅₀: 3375 nM

CDK2, IC₅₀: 823 nM

CDK3, IC₅₀: 1837 nM

CDK5, IC₅₀: >10 (Pan)

CDK6, IC₅₀: 950 nM

CDK7, IC₅₀: 4 nM

CDK9, IC₅₀: 526 nM

CDK12, IC₅₀: >10 (Pan)

CDK9 autophagic degrader 1

CDK9

CDK8-IN-7

CDK8, Kd: 3.5 nM

CDK2-IN-7

CDK2/cyclinE, IC₅₀: 50 nM

CDK4/6-IN-21

CDK4, IC₅₀: 3.88 nM

CDK6, IC₅₀: 3.31 nM

SHP2/CDK4-IN-1

CDK4, IC₅₀: 18.2 ± 1.3 nM

CDK8-IN-5

CDK8, IC₅₀: 72 nM

Anticancer agent 30

CDK2

BMI-1026

CDK1, IC₅₀: 2.3 nM

CDK-IN-14

CDK2/CycA2, IC₅₀: 0.097 μM

JH-VIII-49

CDK8, IC₅₀: 16 nM

Cdc7-IN-18

Cdc7, IC₅₀: 1.29 nM

P162-0948

CDK8, IC₅₀: 50.4 nM

CDK2-IN-40

CDK2/cyclinE, IC₅₀: 10 nM

DDO-6079

CDC37

CDK-TCIP1

CDK9

Cdc7-IN-12

Cdc7, IC₅₀: <1 nM

EF-4-177

CDK2/cyclinE, IC₅₀: 87 nM

SZ-015268

CDK7, IC₅₀: 23.56 nM

PROTAC CDK9 degrader-6

CDK9₄₂, DC₅₀: 0.03 μM
CDK9₅₅, DC₅₀: 0.05 μM

TMX-2172

CDK2, IC₅₀: 6.5 nM

CDK5, IC₅₀: 6.8 nM

PROTAC CDK9/CycT1 Degrader-2

CDK9, IC₅₀: 45 nM

VCC972839:01

CDK9, IC₅₀: 7 nM

CLK1/2-IN-3

CLK1, IC₅₀: 1.1 nM
CLK2, IC₅₀: 2.1 nM

FLT3/ITD-IN-4

CDK16/Cyclin Y, EC₅₀: 1768 nM

PSTAIR

CDC28

CDK4 degrader 1

CDK4

BLINK15

CDK1/Cly Y, IC₅₀: 35.84 nM

CDK2/ClyA2, IC₅₀: 44.12 nM

CDK5/p35, IC₅₀: 29.34 nM
Cdk5/p25, IC₅₀: 12.08 nM

CDK9/Cyclin T, IC₅₀: 74.63 nM

CDK2-IN-29

CDK2, IC₅₀: 96 nM

CDK4, IC₅₀: 360 nM

Autophagy agonist-1

CDK4

3-Methylthienyl-carbonyl-JNJ-7706621

CDK1/cyclinB, IC₅₀: 6.4 nM

CDK2/cyclinA, IC₅₀: 2 nM

CDK4, IC₅₀: 0.11 μM

CDK7-IN-8

CDK7, IC₅₀: 54.29 nM

CDK4/6-IN-9

CDK6/cyclinD1, IC₅₀: 905 nM

Cdc7-IN-19

Cdc7, IC₅₀: 1.49 nM

CDK2/PIM1-IN-1

CDK2, IC₅₀: 0.27 μM

ZLWT-37

CDK2, IC₅₀: 0.054 μM

CDK9, IC₅₀: 0.002 μM

CDK2-IN-26

CDK2

ZDLD13

CDK4/CycD3, IC₅₀: 0.38 μM

CDK1/2/4-IN-1

CDK1, IC₅₀: 1.47

CDK2, IC₅₀: 0.78

CDK4, IC₅₀: 0.87

Antitumor agent-174

CDK1/cyclinB1

CDK-IN-12

CDK4, IC₅₀: <20 nM

CDK6, IC₅₀: <20 nM

CDK8-IN-18

CDK8, IC₅₀: 43 μM

Anticancer agent 29

CDK1/cyclinB1, IC₅₀: 0.127 μM

CDK2/cyclinE, IC₅₀: 0.054 μM

CDK4, IC₅₀: 0.129 μM

CDK6, IC₅₀: 0.396 μM

BSJ-5-63

CDK7

CDK9

CDK12

99.97%

CDK7/9-IN-1

CDK7, IC₅₀: 5.74-65.6 nM

CDK9, IC₅₀: 2.14 μM

CDK12-IN-7

CDK2, IC₅₀: 196 nM

CDK12, IC₅₀: 42 nM

CDK12/13-IN-3

CDK12, IC₅₀: 107.4 nM

CDK13, IC₅₀: 79.4 nM

CDK19 Probe 1

CDK19, IC₅₀: 1.01 μM

CDK12-IN-4

CDK2/cyclinE, IC₅₀: >20 μM

CDK9/cyclinT1, IC₅₀: >20 μM

CDK12, IC₅₀: 0.641 μM

Anticancer agent 264

CDK1/cyclinB1

CDK2/cyclinE

Ulecaciclib

cdk2/cyclin A, Ki: 0.62 μM

Cdk4/cyclin D1, Ki: 0.2 nM

cdk6/cyclin D3, Ki: 3 nM

cdk7-cyclin H, Ki: 0.63 μM

CDK2-IN-28

CDK2, Ki: 1 nM ([1])

CDK5, Ki: 15.8 nM ([1])

CDK7, Ki: 54.7 nM ([1])

CDK9, Ki: 12.8 nM ([1])

NUAK1-IN-2

CDK2

CDK4

CDK6

CDK7-IN-28

cdk2/cyclin A, IC₅₀: 6224 nM

CDK7/Cyclin H/MNAT1, IC₅₀: ＜5 nM

CDK13/Cyclin K, IC₅₀: 152 nM

ZLC491

CDK12

CDK13

PROTAC CDK9 degrader-8

CDK9, IC₅₀: 0.01 μM

CDK7-IN-31

CDK7, Kd: 0.18 nM

PROTAC FLT3/CDKs degrader-1

CDK2, DC₅₀: 18.73 nM

CDK9-IN-32

CDK9

CDK4/6-IN-8

CDK4, IC₅₀: 5.01 nM

CDK6, IC₅₀: 3.97 nM

Indirubin-3'-monoxime-5-sulphonic acid

CDK1, IC₅₀: 5 nM

CDK5, IC₅₀: 7 nM

Multi-kinase-IN-6

CDK2, IC₅₀: 0.71 μM

CLZX-205

CDK9, IC₅₀: 2.9 nM

CDK9-IN-23

CDK9, IC₅₀: <20 nM

EGFR-IN-45

CDK2, IC₅₀: 1.6 μM

CDK-IN-9

CDK2/E, IC₅₀: 4 nM

Cdk5/p25, IC₅₀: 39 nM

CDK9/T1, IC₅₀: 20 nM

CDK12/K, IC₅₀: 64 nM

CDK13/K, IC₅₀: 22 nM

LDC3140

CDK7, IC₅₀: <5 nM

Aloisine RP106

Cdk1/cyclin B, IC₅₀: 0.7 μM

Cdk5/p25, IC₅₀: 1.5 μM

Indirubin-5-sulfonate

Cdk1/cyclin B, IC₅₀: 55 nM

cdk2/cyclin A, IC₅₀: 35 nM
CDK2/cyclinE, IC₅₀: 150 nM

Cdk4/cyclin D1, IC₅₀: 300 nM

CDK5/p35, IC₅₀: 65 nM

PROTAC CDK9 degrader-5

CDK9₄₂, DC₅₀: 0.10 μM
CDK9₅₅, DC₅₀: 0.14 μM

CDK2-IN-42

CDK12

CDK4/6-IN-19

CDK4, IC₅₀: 0.2 nM

CDK6, IC₅₀: 5.0 nM

CDK2-IN-31

CDK2

CDK2-IN-15

CDK2, IC₅₀: 2.9 μM

CDK7-IN-7

CDK7, IC₅₀: <50 nM

TMX-2138

CDK1/cyclinB, IC₅₀: 8.7 nM

CDK2/cyclinA, IC₅₀: 10.9 nM

CDK4/cyclinD1, IC₅₀: 901 nM

Cdk5/p25, IC₅₀: 7.0 nM

CDK6/cyclinD1, IC₅₀: 465 nM

CDK7/cyclin H, IC₅₀: 286 nM

CDK9/cyclinT1, IC₅₀: 25.7 nM

CDK8-IN-15

CDK8, IC₅₀: 57 nM

YJZ5118

CDK12

CDK13

LA-CB1

CDK4

CDK6

CDK7-IN-5

CDK7, IC₅₀: <100 nM

CPD-10

CDK4

Haspin-IN-1

CLK1, IC₅₀: 221 nM

CDK4/6-IN-10

CDK4, IC₅₀: 22 nM

CDK6/cyclinD1, IC₅₀: 10 nM

CDK9-IN-36

CDK9, IC₅₀: 1.2 nM

CDK7-IN-29

CDK7, IC₅₀: 1.4 nM

CDK9/PARP-IN-1

CDK9, IC₅₀: 118 nM

CDK2-IN-44

CDK2

ARN25499

Cdc42

CDK2-IN-14-d₃

CDK2

CDK7-IN-27

CDK2, IC₅₀: 19.4 nM

CDK7, IC₅₀: 3 nM

FLT3/CDK4-IN-1

CDK4, IC₅₀: 7 nM

Isosilybin B (Standard)

CDK2

CDK4

CDK1-IN-4

CDK1, IC₅₀: 44.52 nM

CDK2, IC₅₀: 621.93 nM

CDK5, IC₅₀: 135.22 nM

CDK2-IN-37

CDK2

CDK8/19-IN-2

CDK8/CycC, IC₅₀: 2.08 nM

CDK19/CycC, IC₅₀: 2.49 nM

JTK-101

CDK9/cyclinT1

CDK2-IN-27

CDK1/cyclinB1, IC₅₀: >10-20 nM nM

CDK2/cyclin E1, IC₅₀: <10 nM

CDK9-IN-34

CDK9, IC₅₀: 0.25 μM

2-Cyanoethylalsterpaullone

Cdk1/cyclin B, IC₅₀: 0.23 nM

CCT68127

CDK2

CDK7

CDK9

Olomoucine II

Cdk1/cyclin B, IC₅₀: 7.6 μM

CDK2/cyclinE, IC₅₀: 0.1 μM

CDK4/cyclinD1, IC₅₀: 19.8 μM

CDK7/cyclin H, IC₅₀: 0.45 μM

CDK9/cycT, IC₅₀: 0.06 μM

CDK8-IN-16

CDK8, IC₅₀: 5.1 nM

CDK19, IC₅₀: 5.6 nM

(S)-Roscovitine

CDK1, IC₅₀: ≤1 μM

CDK2, IC₅₀: ≤1 μM

CDK5, IC₅₀: ≤1 μM

CDK7, IC₅₀: ≤1 μM

CDK9, IC₅₀: ≤1 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.

CDK

CDK

CDK Isoform Specific Products:

CDK Isoform Specific Products:

CDK Related Products (821)

Recombinant Proteins (39)

Antibodies (43)

CDK Isoform Comparison

CDK Related Products (821):